Cardinal Health stock: Argus lifts target to $309
Published on 11/16/2026 at 16:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and trading context
- Argus retained its Buy rating while raising its target.
- The target change came after Cardinal Health reported fiscal first-quarter results and a higher full-year outlook.
Argus Research raised its Cardinal Health price target from 264 to 309 US dollars on Thursday, November 12, while maintaining a Buy rating, according to Aries. The analyst action gives investors a new reference point after Cardinal Health's fiscal first-quarter results and higher full-year outlook.
What the target change signals
Aries lists Argus as the latest rating action in its analyst table. The firm kept its Buy view while lifting the target, extending a constructive run of post-results target changes that also includes actions from other Wall Street firms.
The target revision does not change Cardinal Health's operating guidance. It adds an external valuation view to the company's existing earnings and outlook framework, leaving execution in pharmaceutical distribution, specialty services and other businesses as key factors for investors.
Monday trading context
Cardinal Health stock traded at 258.10 euros on Lang & Schwarz at 16:08 CET on Monday, November 16.
Cardinal Health at a glance
- Company: Cardinal Health
- ISIN: US14149Y1082
- Ticker: CAH
- Home exchange: NYSE
- Quote: 258.10 euros on Lang & Schwarz at 16:08 CET on Monday, November 16, 2026
US equity market context is available in Current market reports.
